crypto coins on the rise Top Related searches

Dizhe Pharmaceutical announced that the company's private placement plan has been approved by the Shanghai Stock Exchange. This is the first time that the refinancing of the unprofitable enterprise on the Shanghai Stock Exchange has been approved since the release of "Keba Article".21st century business herald reporter learned exclusively from insiders that this week, the personal pension expansion policy will be announced, "the time may be December 12th". It is reported that the investable products included in personal pension may include over-the-counter products tracking nearly 20 broad-based indexes such as Shanghai and Shenzhen 300 Index, CSI 500 Index, CSI 800 Index, GEM Index and Kechuang 50 Index.Dizhe Pharmaceutical announced that the company's private placement plan has been approved by the Shanghai Stock Exchange. This is the first time that the refinancing of the unprofitable enterprise on the Shanghai Stock Exchange has been approved since the release of "Keba Article".

Exempting the transfer of shares or units of REITs and the securities distribution business of option makers will enhance the competitiveness of Hong Kong REITs and reduce the transaction costs of option makers. Revising the stamp duty collection arrangement will promote the efficiency of stamping and stamp duty collection procedures in the paperless securities market environment.This is a real long-term positive, which is manifested in three aspects: first, it is conducive to attracting investors to invest in the broad-based index through personal pension accounts; Second, it is helpful to inject new long-term funds into the capital market, optimize the investor structure, stabilize the market and promote the healthy development of the capital market; Third, it reflects the care of the regulatory authorities for the capital market and helps to enhance investors' confidence.The latest news of personal pension fund, incremental funds are coming!

Statement: Personal opinion, for reference only!A shares: the latest release of Shanghai Stock Exchange! Incremental funds are coming, and it is likely to continue to rise on Thursday!Dezhe Medicine is a listed company in science and technology innovation board, and it is an innovation-driven biomedical company with global competitiveness. Therefore, its refinancing has been approved by the Shanghai Stock Exchange, which also shows that the supervision is tolerant of companies with core technology and hard power. Although it may not be ideal financially for the time being, it has broad prospects and great imagination, which is worthy of support.